Biomimetic Diselenide-Bridged Mesoporous Organosilica Nanoparticles as an X-ray-Responsive Biodegradable Carrier for Chemo-Immunotherapy

Biomimetic Diselenide-Bridged Mesoporous Organosilica Nanoparticles as an X-ray-Responsive Biodegradable Carrier for Chemo-Immunotherapy

© 2020 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 32(2020), 50 vom: 01. Dez., Seite e2004385
1. Verfasser: Shao, Dan (VerfasserIn)
Weitere Verfasser: Zhang, Fan, Chen, Fangman, Zheng, Xiao, Hu, Hanze, Yang, Chao, Tu, Zhaoxu, Wang, Zheng, Chang, Zhimin, Lu, Junna, Li, Tianyu, Zhang, Yuan, Chen, Li, Leong, Kam W, Dong, Wen-Fei
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article X-ray radiation responsivity biodegradable mesoporous organosilica nanoparticles biomimetic chemo-immunotherapy diselenide bonds Doxorubicin 80168379AG Drug Carriers Reactive Oxygen Species mehr... Organosilicon Compounds Organoselenium Compounds
Beschreibung
Zusammenfassung:© 2020 Wiley-VCH GmbH.
Chemotherapy causes off-target toxicity and is often ineffective against solid tumors. Targeted and on-demand release of chemotherapeutics remains a challenge. Here, cancer-cell-membrane-coated mesoporous organosilica nanoparticles (MONs) containing X-ray- and reactive oxygen species (ROS)-responsive diselenide bonds for controlled release of doxorubicin (DOX) at tumor sites are developed. DOX-loaded MONs coated with 4T1 breast cancer cell membranes (CMMON@DOX) show greater accumulation at tumor sites and prolonged blood circulation time versus an uncoated control in mice bearing 4T1 orthotopic mammary tumors. Under low-dose X-ray radiation, the DOX-loaded MONs exhibit carrier degradation-controlled release via cleavage of diselenide bonds, resulting in DOX-mediated immunogenic cell death at the tumor site. Combination with a PD-L1 checkpoint blockade further enhances inhibition of tumor growth and metastasis with low systemic toxicity. Together, the findings show the promise of these biomimetic, radiation-responsive diselenide-bond-bridged MONs in chemo-immunotherapy
Beschreibung:Date Completed 24.07.2024
Date Revised 24.07.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202004385